Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-17T23:33:41.176Z Has data issue: false hasContentIssue false

Authors' reply

Published online by Cambridge University Press:  02 January 2018

Lars Vedel Kessing
Affiliation:
Department of Psychiatry, Rigshospitalet, University Hospital of Copenhagen, 2100 Copenhagen, Denmark, email: Lars.Vedel.Kessing@regionh.dk
Per Kragh Andersen
Affiliation:
Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark
Rights & Permissions [Opens in a new window]

Abstract

Type
Columns
Copyright
Copyright © Royal College of Psychiatrists, 2011 

We thank Dr Vanderburg and colleagues for their comments on our paper. We used observational, non-randomised, routinely collected data to describe the rate of incident diabetes among patients treated with antipsychotics in clinical practice. These data reflect the way antipsychotics are handled by individual clinicians on the basis of their knowledge of effects and side-effects for the specific patient. Findings from analyses of our data cannot be used to infer causality between individual antipsychotics and diabetes and may be at odds with findings from randomised trials and other studies aimed at testing specific hypotheses. Our results on the individual antipsychotics describe the prevalence of diabetes among patients for whom the clinician decided to prescribe a given antipsychotic.

References

Edited by Kiriakos Xenitidis and Colin Campbell

Declaration of interest

L.V.K. has been a consultant for Bristol-Myers Squibb, Eli Lilly, Lundbeck, AstraZenica, Pfizer, Wyeth, Servier and Janssen-Cilag.

Submit a response

eLetters

No eLetters have been published for this article.